Evaluation of intravenous voriconazole in patients with compromised renal function
详细信息 查看全文
- 作者：Craig M Lilly (1)
Verna L Welch (2)
Thomas Mayer (1)
Paul Ranauro (1)
Joanne Meisner (1)
David R Luke (2) - 关键词：Voriconazole ; Caspofungin ; Fluconazole ; Renal dysfunction ; Sulfobutylether ; β ; cyclodextrin ; SBECD ; Acute kidney injury
- 刊名：BMC Infectious Diseases
- 出版年：2013
- 出版时间：December 2013
- 年：2013
- 卷：13
- 期：1
- 全文大小：211KB
- 参考文献：1. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. / NEJM 2003, 348:1546-554. CrossRef
2. Wisplinghoff H, Seiffert H, Wenzel RP, Edmond MB: Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. / Clin Infect Dis 2003, 36:1103-110. CrossRef
3. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP, The National Nosocomial Infections Surveillance System Hospitals: Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States. / Clin Infect Dis 2002, 35:627-30. CrossRef
4. Marr KA, Carter RA, Boeckh M, Martin P, Corey L: Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. / Blood 2002, 100:4358-366. CrossRef
5. Zilberberg MD, Shorr AF: Fungal infections in the ICU. / Infect Dis Clin North Am 2009, 23:625-42. CrossRef
6. Pemán J, Luque P, Nieto M, Pozo JC, Solé A, Zaragoza R: Update on invasive mycoses by filamentous fungi in critically ill patients. / Enferm Infecc Microbiol Clin 2011, 29:36-1. CrossRef
7. Pagano L, Girmenia C, Mele L, / et al.: Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA infection program. / Haematologica 2001, 86:862-70.
8. Panackal AA, Marr KA: Scedosporium/Pseudoallescheria infections. / Semin Respir Crit Care Med 2004, 25:171-81. CrossRef
9. Frank DW, Gray JE, Weaver RN: Cyclodextrin nephrosis in the rat. / Am J Pathol 1976, 83:367-82.
10. Luke DR, Reisman A, Schlamm HT: / Renal effects of intravenous voriconazole in patients with compromised renal function. Boston MA, USA; 2010. [ / Proceedings of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy]
11. Luke DR, Tomaszewski K, Damle B, Schlamm HT: Review of the basic and clinical pharmacology of sulfobutylether-β-cyclodextrin (SBECD). / J Pharm Sci 2010, 99:3291-301. CrossRef
12. Pfizer Inc: / Vfend (voriconazole) package insert. New York, NY; 2011.
13. Sanati H, Belanger P, Fratti R, Ghannoum M: A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei . / Antimicrob Agents Chemother 1997, 41:2492-496.
14. Roffey SJ, Cole S, Comby P, / et al.: The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. / Drug Metab Dispos 2003, 31:731-41. CrossRef
15. Oude Lashof AML, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Schamm HT, Rex JH, Kullberg BJ: Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia. / Antimicrob Agents Chemother 2012, 56:3133-137. CrossRef
16. Von Mach MA, Burhenne J, Weilemann LS: Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. / BMC Clin Pharmacol 2006, 6:1-. CrossRef
17. Luke DR, Wood ND, Tomaszewski KE, Damle B: Pharmacokinetics of sulfobutylether-β-cyclodextrin (SBECD) in subjects on hemodialysis. / Nephrol Dial Transplant 2012, 27:1207-212. CrossRef
18. Hafner V, Czock D, Burhenne J, / et al.: Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemofiltration. / Antimicrob Agents Chemother 2010, 54:2596-602. CrossRef
19. Abel S, Allan R, Gandelman K, Tomaszewski K, Webb DJ, Wood ND: Pharmacokinetics, safety, and tolerance of voriconazole in renally impaired subjects. / Clin Drug Invest 2008, 28:409-20. CrossRef
20. Potoski BA, Sima AP: / Effect of intravenous voriconazole on serum creatinine in a population of patients with stable renal function. Washington, DC, USA; 2008. [ / Proceedings of the 48th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy]
21. Neofytos D, Lombardi LR, Shields RK, Ostrander D, Warren L, Nguyen MH, Thompson CB, Marr KA: Administration of voriconazole in patients with renal dysfunction. / Clin Infect Dis 2012, 54:913-21. CrossRef
22. Pfizer Inc: / Diflucan (fluconazole) package insert. New York, NY; 2011.
23. Kellum JA, Levin N, Bouman C, Lamiere N: Developing a consensus classification system for acute renal failure. / Curr Opin Crit Care 2002, 8:509-14. CrossRef
24. Aloui S, Gorcii M, Skhiri H, / et al.: Acute renal failure and fungus ball: a case report. / Nephrol Therapeut 2010, 6:171-72. CrossRef
25. Aysel K, Alev Y, Nur C, Gonul A, Serdar S, Orhan K: Acute renal failure caused by fungal balls in renal pelvises. / Pediatr Int 2009, 51:836-38. CrossRef
26. Dervisoglu E, Dikmen E, Filinte D, Yilmaz A: Isolated bladder aspergillosis as the primary presentation of non-oliguric acute renal failure. / Scan J Urol Nephrol 2008, 42:189-91. CrossRef
27. Filipowicz J, Kozlowski M, Irga N, Szalewska M, Zurowska A, Slusarczyk M: Acute renal insufficiency during Candida albicans candidiasis in a 2-month old infant. / Przegl Lek 1997, 54:73-5.
28. Scerpella EG, Alhalel R: An unusual case of acute renal failure: bilateral ureteral obstruction due to Candida tropicalis fungus balls. / Clin Infect Dis 1994, 18:440-42. CrossRef
29. Shimada S, Nakagawa H, Shintaku I, Saito S, Arai Y: Acute renal failure as a result of bilateral ureteral obstruction by Candida albicans fungus balls. / Int J Urol 2006, 13:1121-122. CrossRef
30. Tekin N, Kural N, Kaya T, ?lhan H: Acute renal failure in two infants due to ureteropelvic fungi balls. / Pediatr Int 2002, 44:112-14. CrossRef
31. Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J: Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. / Bone Marrow Transplant 2001, 28:873-78. CrossRef
32. Nishimoto G, Tsunoda Y, Nagata M, Yamaguchi Y, Yoshioka T, Ito K: Acute renal failure associated with Candida albicans infection. / Pediatr Nephrol 1995, 9:480-82. CrossRef
33. Noris M, Caprioli J, Bresin E, / et al.: Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. / Clin J Am Soc Nephrol 2010, 5:1844-859. CrossRef
34. De Pauw B, Walsh TJ, Donnelly JP, / et al.: Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycology study group (EORTC/MSG) consensus group. / Clin Infect Dis 2008, 46:1813-821. CrossRef
35. Roberts GW, Ibsen PM, Teglman Schi?ler C: Modified diet in renal disease method overestimates renal function in selected elderly patients. / Age Ageing 2009, 38:698-03. CrossRef
36. Nyman HA, Dowling TC, Hudson JQ, St Peter WL, Joy MS, Nolin TD: Comparative evaluation of the Cockcroft-Gault equation and the modification of diet in renal disease (MDRD) study equation for drug dosing: an opinion of the nephrology practice and research network of the American college of clinical pharmacy. / Pharmacother 2011, 31:1130-144. CrossRef
37. Cockcroft GW, Gault MH: Prediction of creatinine clearances from serum creatinine. / Nephron 1976, 16:31-1. CrossRef
38. Wilhelm SM, Kale-Pradham PB: Estimating creatinine clearance: a meta-analysis. / Pharmacother 2011, 31:658-64. CrossRef
39. Luke DR, Halstenson CE, Opsahl JA, Matzke GR: Validity of creatinine clearance estimates in the assessment of renal function. / Clin Pharmacol Ther 1990, 48:503-08. CrossRef
40. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. / Ann Intern Med 1999, 130:461-70.
41. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/13/14/prepub - 作者单位：Craig M Lilly (1)
Verna L Welch (2)
Thomas Mayer (1)
Paul Ranauro (1)
Joanne Meisner (1)
David R Luke (2)
1. University of Massachusetts Medical School, Worcester, Massachusetts, USA
2. Medical Affairs, Pfizer Inc, Collegeville, Pennsylvania, USA
文摘
Background Incorporation of the solubilizing excipient, sulfobutylether-β-cyclodextrin (SBECD), in the intravenous (IV) formulation of voriconazole has resulted in the recommendation that this formulation be used with caution in patients with creatinine clearances (Clcr)-lt;-0 mL/min. This study evaluated the safety of IV voriconazole compared with two other IV antifungals not containing SBECD in patients with compromised renal function. Methods A total of 128 patients aged 11-3 years who had a baseline Clcr-lt;-0 mL/min between January 1, 2007 and December 31, 2010 were identified from a database of a university-affiliated inpatient healthcare system; of these, 55 patients received caspofungin, 54 patients received fluconazole, and 19 patients received voriconazole. Changes in serum creatinine (Scr) and Clcr levels while on therapy were compared with baseline values and between groups. Results The groups had similar characteristics apart from the larger proportion of females that received fluconazole. Baseline Scr was higher in those receiving caspofungin, but maximal increases of Scr and decreases in Clcr were greatest for the fluconazole group. Acute kidney injury (AKI), assessed by RIFLE criteria, was more frequent in the fluconazole vs. the caspofungin group (p-lt;-.01); incidence of AKI in the voriconazole group was not significantly different than found in the other two groups. The infecting organism was a predictor of AKI and formulation with SBECD was not. Conclusions Treatment of fungal infections in patients with compromised renal function with an SBECD-containing antifungal agent was not associated with AKI in clinical practice. Since the infecting organism was associated with AKI, decision on which antifungal to use should be determined by susceptibilities to the organism and not the incorporation of SBECD in the IV formulation.